You are leaving Medscape Education
Cancel Continue
Log in to save activities Your saved activities will show here so that you can easily access them whenever you're ready. Log in here CME & Education Log in to keep track of your credits.



Interprofessional Skills Challenge for a Potential Post-Transplant Complication

  • Authors: Angela Smith, MD, MS
  • CME / ABIM MOC / CE Released: 10/31/2019
  • Valid for credit through: 10/31/2020
Start Activity

Target Audience and Goal Statement

This activity is intended for hematologists/oncologists, nurses, and pharmacists.

The goal of this activity is to educate clinicians on the prevention, monitoring, and management of an important post-transplant complication.

Upon completion of this activity, participants will:

  • Have greater competence related to
    • Implementing appropriate preventive measures for a potential complication after HSCT
    • Incorporating results of laboratory tests, imaging studies, and patients' symptom reports to make a diagnosis of a potential complication after HSCT
    • Managing a potential complication of HSCT with appropriate treatment and follow-up measures
  • Demonstrate greater confidence in their ability to
    • Provide team-based care for patients who develop a potential complication after HSCT


As an organization accredited by the ACCME, Medscape, LLC, requires everyone who is in a position to control the content of an education activity to disclose all relevant financial relationships with any commercial interest. The ACCME defines "relevant financial relationships" as financial relationships in any amount, occurring within the past 12 months, including financial relationships of a spouse or life partner, that could create a conflict of interest.

Medscape, LLC, encourages Authors to identify investigational products or off-label uses of products regulated by the US Food and Drug Administration, at first mention and where appropriate in the content.


  • Angela R. Smith, MD

    University of Minnesota
    Minneapolis, Minnesota


    Disclosure: Angela Smith, MD, MS, has disclosed no relevant financial relationships.

  • Alison Bemis, RN-BC, CPNP-AC

    Pediatric Blood and Marrow Transplant Program
    University of Minnesota Masonic Children's
    Minneapolis, Minnesota


    Disclosure: Alison Bemis, RN-BC, CPNP-AC, has disclosed no relevant financial relationships.

  • Cathryn Jennissen, PharmD, BCOP

    Clinical Pediatric Pharmacist
    Blood and Marrow Transplant Program
    Minneapolis, Minnesota


    Disclosure: Cathryn Jennissen, PharmD, BCOP, has disclosed no relevant financial relationships.


  • Mindy Tanzola, PhD

    Medical Education Director, Medscape, LLC


    Disclosure: Mindy Tanzola, PhD, has disclosed no relevant financial relationships.

  • Tristin Abair, PhD

    Senior Medical Writer, Medscape, LLC


    Disclosure: Tristin Abair, PhD, has disclosed no relevant financial relationships.

CME/CE Reviewer, Nurse Planner

  • Hazel Dennison, DNP, RN, FNP

    Associate Director, Accreditation and Compliance, Medscape, LLC


    Disclosure: Hazel Dennison, DNP, RN, FNP, CPHQ, CNE, has disclosed no relevant financial relationships.

Medscape, LLC staff have disclosed that they have no relevant financial relationships.

Accreditation Statements


In support of improving patient care, Medscape, LLC is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

This activity was planned by and for the healthcare team, and learners will receive 1.0 Interprofessional Continuing Education (IPCE) credit for learning and change.

    For Physicians

  • Medscape, LLC designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit(s)™ . Physicians should claim only the credit commensurate with the extent of their participation in the activity.

    Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 1.0 MOC points in the American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit. Aggregate participant data will be shared with commercial supporters of this activity.

    Contact This Provider

    For Nurses

  • Awarded 1.0 contact hour(s) of continuing nursing education for RNs and APNs; 1.0 contact hours are in the area of pharmacology.

    Contact This Provider

    For Pharmacists

  • Medscape, LLC designates this continuing education activity for 1.00 contact hour(s) (0.100 CEUs) (Universal Activity Number JA0007105-0000-19-476-H01-P).

    Contact This Provider

For questions regarding the content of this activity, contact the accredited provider for this CME/CE activity noted above. For technical assistance, contact [email protected]

Instructions for Participation and Credit

There are no fees for participating in or receiving credit for this online educational activity. For information on applicability and acceptance of continuing education credit for this activity, please consult your professional licensing board.

This activity is designed to be completed within the time designated on the title page; physicians should claim only those credits that reflect the time actually spent in the activity. To successfully earn credit, participants must complete the activity online during the valid credit period that is noted on the title page. To receive AMA PRA Category 1 Credit™, you must receive a minimum score of 70% on the post-test.

Follow these steps to earn CME/CE credit*:

  1. Read the target audience, learning objectives, and author disclosures.
  2. Study the educational content online or printed out.
  3. Online, choose the best answer to each test question. To receive a certificate, you must receive a passing score as designated at the top of the test. We encourage you to complete the Activity Evaluation to provide feedback for future programming.

You may now view or print the certificate from your CME/CE Tracker. You may print the certificate but you cannot alter it. Credits will be tallied in your CME/CE Tracker and archived for 6 years; at any point within this time period you can print out the tally as well as the certificates from the CME/CE Tracker.

*The credit that you receive is based on your user profile.


Interprofessional Skills Challenge for a Potential Post-Transplant Complication

Authors: Angela Smith, MD, MSFaculty and Disclosures

CME / ABIM MOC / CE Released: 10/31/2019

Valid for credit through: 10/31/2020


The following cases are modeled on the interactive grand rounds approach. The questions within the activity are designed to test your current knowledge. After each question, you will be able to see whether you answered correctly and read evidence-based information that supports the most appropriate answer choice. The questions are designed to challenge you; you will not be penalized for answering the questions incorrectly. At the end of the activity, there will be a short post-test assessment based on the material presented. The goal of this activity is to educate clinicians on the prevention, monitoring, and management of an important post-transplant complication.


Patient History and Presentation

Angela is a fit, 35-year-old who was recently diagnosed with AML. She initially presented to her family physician with flu-like symptoms and fatigue that had been present for more than 2 weeks. Prior to this she was healthy with no history of major medical issues. Her medications included oral contraceptives daily, loratadine as needed for seasonal allergies, and acetaminophen as needed for joint pain. Her WBC count was 2.8 cells/mm3, hemoglobin was 9 g/dL, neutrophil count was 1100/mm3, and platelet count was 40,000/μL. Other laboratory tests were normal, including liver and kidney function, and echocardiogram showed normal ejection fraction. Bone marrow biopsy showed 48% blasts. Cytogenetics were normal and molecular testing identified wild-type NPM1 with no FLT3-ITD mutation. Immunophenotyping showed 75% of blasts were positive for CD33. She was treated with 7+3 (cytarabine/daunorubicin) induction therapy with gemtuzumab ozogamicin administered on days 1, 4, and 7, followed by 2 cycles of consolidation with cytarabine/daunorubicin with gemtuzumab ozogamicin given on day 1.

Angela achieved a CR and is now ready to begin myeloablative conditioning with busulfan and cyclophosphamide, followed by allogeneic HSCT from a matched sibling donor.

  • Print